New therapeutic options in psoriasis

2021 ◽  
Vol 97 (5) ◽  
pp. 245-250
Author(s):  
Péter Holló ◽  
◽  
Éva Anna Piros ◽  
Rolland Gyulai
Keyword(s):  
Adverse Events ◽  
Targeted Therapies ◽  
Biological Therapy ◽  
Severe Psoriasis ◽  
Therapeutic Options ◽  
Specific Inhibition ◽  
New Agents ◽  
The Future ◽  
History Of ◽  
Modern Treatment

The biological therapy of moderate-to-severe psoriasis has a history of almost two decades. During this period our knowledge of the pathomechanism of the disease has become more accurate, leading to the development of more and more targeted therapies. Increased efficacy through more specific inhibition is accompanied by less adverse events. In this article, the authors summarize the current possibilities for the modern treatment of psoriasis and the key clinical insights into these options. They discuss the future therapeutic directions and new agents.

scholarly journals A Six-Year Analysis of Biological Therapy for Severe Psoriasis in a Lithuanian Reference Centre of Dermatovenereology

Medicina ◽  
2020 ◽  
Vol 56 (6) ◽  
pp. 275
Author(s):  
Tadas Raudonis ◽  
Akvile Gliebute ◽  
Anna Greta Grigaityte ◽  
Zivile Lukosiunaite ◽  
Tatjana Karmaziene ◽  
...  
Keyword(s):  
Adverse Events ◽  
Biological Therapy ◽  
Severity Index ◽  
Severe Psoriasis ◽  
Impaired Liver Function ◽  
Results Of Treatment ◽  
Reference Centre ◽  
Duration Of Illness ◽  
Impaired Liver ◽  
Baseline Bmi

Background and Objectives: Biological therapy is widely used for the treatment of severe psoriasis. The objective of this study was to evaluate the efficacy and safety of biological therapy for patients with severe psoriasis. Materials and Methods: A retrospective study of 79 patients with severe psoriasis, who have been treated with biological therapy between 2012 and 2018, was conducted. During this study, the following data were collected and evaluated: sex, age, body mass index (BMI), duration of illness, the results of treatment with biological therapy, concomitant therapy, Psoriasis Area and Severity Index (PASI) and adverse events. Results: In total, 74.7% (n = 59) of subjects were male. Their overall average age was 47.4 ± 11.4 (range: 18–73) years. Their baseline BMI was 27.6 ± 5.9, which increased to 29.6 ± 4.5 after 6 years of treatment. The mean duration of psoriasis was 25.7 ± 12.5 years. In total, 39.2% (n = 31) of subjects received infliximab, 36.7% (n = 29)—etanercept, 24.1% (n = 19)—ustekinumab. The treatment duration for infliximab, etanercept and ustekinumab was 201.6 ± 86.8, 156.2 ± 137.4 and 219.1 ± 95.7 weeks (p < 0.01), respectively. Overall, 65.8% (n = 52) of subjects were also on methotrexate; 30.8% (n = 16) of them discontinued it due to clinical improvement (31.3% (n = 5)), impaired liver function (31.3% (n = 5)), and intolerance (25% (n = 4)). Baseline PASI was 20.8 ± 8.8. PASI 50 was achieved by 96.2% (n = 76) of patients at week 11, PASI 75 by 86.1% (n = 68) at week 16, PASI 90 by 54.4% (n = 43) at week 35, and PASI 100 by 13.9% (n = 11) at week 33. The overall incidence rate of adverse events was 0.362 per patient year of follow-up. Conclusion: Biological therapy is an effective and safe treatment for patients with severe psoriasis.

scholarly journals Combinatorial Therapies in Thyroid Cancer: An Overview of Preclinical and Clinical Progresses

Cells ◽  
2020 ◽  
Vol 9 (4) ◽  
pp. 830 ◽  
Author(s):  
Gheysen Laetitia ◽  
Saussez Sven ◽  
Journe Fabrice
Keyword(s):  
Thyroid Cancer ◽  
Signaling Pathways ◽  
Targeted Therapies ◽  
Therapeutic Strategies ◽  
Therapeutic Options ◽  
Clinical Aspects ◽  
Preclinical Studies ◽  
The Future ◽  
Made In

Accounting for about 2% of cancers diagnosed worldwide, thyroid cancer has caused about 41,000 deaths in 2018. Despite significant progresses made in recent decades in the treatment of thyroid cancer, many resistances to current monotherapies are observed. In our complete review, we report all treatments that were tested in combination against thyroid cancer. Many preclinical studies investigating the effects of inhibitors of the MAPK and PI3K pathways highlighted the importance of mutations in such signaling pathways and their impacts on the subsequent efficacy of targeted therapies, thus reinforcing the need of more personalized therapeutic strategies. Our review also points out the multiple possibilities of combinatory strategies, particularly using therapies targeting proliferation, survival, angiogenesis, and in combination with conventional treatments such as chemotherapies. In any case, resistances to anticancer therapies always develop through the activation of alternative signaling pathways. Combinatory treatments aim to blockade such mechanisms, which are gradually decrypted, thus offering new perspectives for the future. The preclinical and clinical aspects of our review allow us to have a global opinion of the different therapeutic options currently evaluated in combination and to be aware about new perspectives of treatment of thyroid cancer.

scholarly journals Baseline Comorbidities in a Population-Based Cohort of Rheumatoid Arthritis Patients Receiving Biological Therapy: Data from the Australian Rheumatology Association Database

2009 ◽  
Vol 2009 ◽  
pp. 1-8 ◽  
Author(s):  
Andrew M. Briggs ◽  
Lyn March ◽  
Marissa Lassere ◽  
Christopher Reid ◽  
Lyndall Henderson ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Adverse Events ◽  
Biological Therapy ◽  
Biologic Therapy ◽  
Descriptive Analysis ◽  
Population Based ◽  
Comorbid Condition ◽  
Australian Population ◽  
History Of ◽  
Baseline Characteristics

Aims. To describe the baseline characteristics of an Australian population-based cohort of rheumatoid arthritis (RA) patients commencing biological therapy.Methods. Descriptive analysis from the Australian Rheumatology Association Database (ARAD).Results. Up to October 2006, there were 681 RA patients taking biologics enrolled in ARAD. Baseline data were available for 624 (72% female, mean (SD) age 57.0 (12.5) years). Of these, 59.5% reported at least one comorbid condition, most commonly hypertension (35.7%) and osteoporosis (30.4%); 61 (9.8%) had a history of malignancy (35 nonmelanoma skin, 5 breast, 4 bowel, 5 cervix, 3 melanoma, 3 prostate and 1 each of lip, lung, myeloma, testis, uterus, vagina). Self-reported infections within the previous 6 months were common (71.5%).Conclusions. History of comorbidities, including recent infections, is common among Australian RA patients commencing biologics, and 10% have a history of malignancy. This may impact future evaluations of health outcomes among this population, including attribution of adverse events of biologic therapy.

A Dynamic Systems Approach to Personality

2001 ◽  
Vol 6 (3) ◽  
pp. 172-176 ◽  
Author(s):  
Lawrence A. Pervin
Keyword(s):  
Dynamic Systems ◽  
Systems Approach ◽  
Biological Processes ◽  
Recent Advances ◽  
Dynamic View ◽  
The Future ◽  
History Of

David Magnusson has been the most articulate spokesperson for a holistic, systems approach to personality. This paper considers three concepts relevant to a dynamic systems approach to personality: dynamics, systems, and levels. Some of the history of a dynamic view is traced, leading to an emphasis on the need for stressing the interplay among goals. Concepts such as multidetermination, equipotentiality, and equifinality are shown to be important aspects of a systems approach. Finally, attention is drawn to the question of levels of description, analysis, and explanation in a theory of personality. The importance of the issue is emphasized in relation to recent advances in our understanding of biological processes. Integrating such advances into a theory of personality while avoiding the danger of reductionism is a challenge for the future.

A Reflection on Crucial Periods in 50 Years of Social Psychology (in Germany)

2019 ◽  
Vol 50 (1) ◽  
pp. 1-6
Author(s):  
Katja Corcoran ◽  
Michael Häfner ◽  
Mathias Kauff ◽  
Stefan Stürmer
Keyword(s):  
Social Psychology ◽  
Early Development ◽  
West Germany ◽  
East And West Germany ◽  
The Future ◽  
History Of ◽  
East And West

Abstract. In this article, we reflect on 50 years of the journal Social Psychology. We interviewed colleagues who have witnessed the history of the journal. Based on these interviews, we identified three crucial periods in Social Psychology’s history, that are (a) the early development and further professionalization of the journal, (b) the reunification of East and West Germany, and (c) the internationalization of the journal and its transformation from the Zeitschrift für Sozialpsychologie to Social Psychology. We end our reflection with a discussion of changes that occurred during these periods and their implication for the future of our field.

The future of the history of psychology in Argentina and Brazil.

2016 ◽  
Vol 19 (3) ◽  
pp. 229-247 ◽  
Author(s):  
Hugo Klappenbach ◽  
Ana Maria Jacó-Vilela
Keyword(s):  
History Of Psychology ◽  
The Future ◽  
History Of

Karl Marx’s Legacy: The Historical Overview

2007 ◽  
pp. 87-103
Author(s):  
R. Nureev
Keyword(s):  
Marxist Theory ◽  
Neoclassical Economic ◽  
Historical Overview ◽  
Economic Theories ◽  
The Future ◽  
History Of ◽  
Western Marxism

The article is devoted to the history of reception and interpretation of the ideas of Marx and Engels. The author considers the reasons for divergence between Marxist and neoclassical economic theories. He also analyzes the ways of vulgarization of Marx’s theory and the making of Marxist voluntarism. It is shown that the works of Marx and Engels had a certain potential for their over-simplified interpretations. The article also considers academic ("Western") Marxism and evaluates the prospects of Marxist theory in the future.

Sign in / Sign up

Export Citation Format

Share Document